Creative Medical gained 4.7% after the FDA granted fast track status to CELZ-201-DDT for degenerative disc disease, a $20 billion+ potential market by 2030. The allogeneic cell therapy aims to treat root causes of back pain. The designation speeds FDA review, boosting hopes for faster approval. Retail sentiment surged 3,600%, with traders eyeing sharp upside.